CARLOS
SOLANO VERCET
CATEDRÁTICO/A DE UNIVERSIDAD
Rafael
Duarte Palomino
Publicacions en què col·labora amb Rafael Duarte Palomino (14)
2024
-
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
The Lancet Haematology, Vol. 11, Núm. 2, pp. e147-e159
-
Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir
Clinical Infectious Diseases, Vol. 78, Núm. 3, pp. 562-572
2021
-
Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group
Transplant Infectious Disease, Vol. 23, Núm. 4
2020
-
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
Frontiers in Immunology, Vol. 11
-
Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Bone Marrow Transplantation, Vol. 55, Núm. 4, pp. 681-694
-
Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) (Bone Marrow Transplantation, (2020), 55, 4, (681-694), 10.1038/s41409-019-0718-7)
Bone Marrow Transplantation
-
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
The Lancet Haematology, Vol. 7, Núm. 2, pp. e157-e167
2019
-
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant
Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1825-1831
2017
-
Single umbilical cord blood with or without CD341 cells from a third-party donor in adults with leukemia
Blood Advances, Vol. 1, Núm. 15, pp. 1047-1055
2016
-
Antilymphocyte globulin for prevention of chronic graft-versus-host disease
New England Journal of Medicine, Vol. 374, Núm. 1, pp. 43-53
-
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico
Biology of Blood and Marrow Transplantation, Vol. 22, Núm. 3, pp. 584-588
2015
-
Outcome of graft failure after allogeneic stem cell transplant: Study of 89 patients
Leukemia and Lymphoma, Vol. 56, Núm. 3, pp. 656-662
2014
-
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation
Haematologica, Vol. 99, Núm. 10, pp. 1632-1637
2010
-
Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source
Biology of Blood and Marrow Transplantation, Vol. 16, Núm. 7, pp. 957-966